Welcome to ProbeChem!Global Supplier of Chemical Probes, Inhibitors & Agonists.
Chemical Structure : MK256
Catalog No.: PC-49444Not For Human Use, Lab Use Only.
MK256 (MK-256) is a potent, selective CDK8 inhibitor with IC50 of 2.5 nM and 3.3 nM against CDK8/cyclin C and CDK19/cyclin C, respectively.
Bulk size, bulk discount!
E-mail: sales@probechem.com
Tech Support: tech@probechem.com
MK256 (MK-256) is a potent, selective CDK8 inhibitor with IC50 of 2.5 nM and 3.3 nM against CDK8/cyclin C and CDK19/cyclin C, respectively.
MK256 does not inhibit other 13 CDKs at 200 nM, with exception of CDK9 (IC50=105 nM, 40-fold selectivity for CDK8).
MK256 bonds in the ATP binding pocket of CDK8, two hydrogen bonds were formed between MK256 and hinge region residues Asp98 and Ala100.
MK256 (50-500 nM) induces differentiation/maturation in CD34+/CD38- human leukemic cell line (TEX) cells.
MK256 shows a wide range of sensitivity to a panel of AML cell lines, ranging from highly sensitive (<30 nM) to highly resistant (>5 uM).
MK256 is sensitive to MV- 4-11 (IC50=23 nM) and MOLM-14 (IC50=24 nM), both of which harbor mixed lineage leukemia (MLL) fusions.
MK256 also shows relatively potent growth inhibition against SKNO-1 (IC50=73 nM) and KG-1 (IC50=80 nM).
MK256 downregulates phosphorylation of STAT1 and STAT5 in AML cell lines MV-4-11 and MOLM-14, also downregulates MCL-1 and CCL2 mRNA expression.
MK256 (50 mg/kg, oral) showed great efficacy in MOLM-14 mice xenograft model, the combination of MK256 and venetoclax lowered the effective concentration for both compounds.
| M.Wt | 317.142 | |
| Formula | C14H9BrN2O2 | |
| Appearance | Solid | |
| Storage |
|
|
| Solubility |
10 mM in DMSO |
|
1. Jen-Chieh Lee, et al. Oncotarget. 2022 Nov 2;13:1217-1236.
Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright
